Education: MSc, Industrial Engineering and Management (focus on Biotech) from Chalmers University of Technology with a Master degree in Innovation and Entrepreneurship from Chalmers School of Entrepreneurship (Biotech), 2006.
Experience: Jamal El-Mosleh (born 1981) most recently comes from a position as CEO of First North-listed biotechnology company Annexin Pharmaceuticals AB (publ) (2017-2019). Prior to that, he was CEO for nearly ten years at Small Cap-listed immuno-oncology company Immunicum AB (2007-2017) (now Mendus). As the first employee in 2007, he acted as co-founder of the company and was responsible for Immunicum's listing on NASDAQ First North in 2013 and the initiation of a broad international clinical program. Jamal El-Mosleh was also a board member of the cancer diagnostics company Elypta AB (2017-2020).
Shares: 2 895 300 (incl. related parties).
Warrants (TO2): 151 900 (incl. related parties).
